LYBALVI

AssetAlso ALKS 3831, Samidorphan + olanzapine

Combination of olanzapine with samidorphan, an opioid receptor antagonist to mitigate weight gain

Stage: Phase 2
Modality: Small molecule
Target: HTR2A; 3
Indications: 225
Trials: 1
Developer

Indications

3

Alcohol use disorder
Phase 2, Completed, NCT02161718, clinicaltrials.gov, 8 Oct 2026
Schizophrenia
Phase 2, Completed, NCT02161718, clinicaltrials.gov, 8 Oct 2026
Focus of study is on healthy lactating women
Phase 1, Completed, NCT05547100, clinicaltrials.gov, 8 Oct 2026

In the full profile

Targets and what it contains4
Owner and partners1
Trials225
Evidence for its targets3
Competitors12

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 8 Oct 2026, 3 sources